✦ LIBER ✦

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers

✍ Scribed by Thong P. Le; Kevin M. Coonan; Richard C. Hedstrom; Yupin Charoenvit; Martha Sedegah; Judith E. Epstein; Sanjai Kumar; Ruobing Wang; Denise L. Doolan; Jason D. Maguire; Suezanne E. Parker; Peter Hobart; Jon Norman; Stephen L. Hoffman

Book ID: 117433694
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 147 KB
Volume: 18
Category: Article
ISSN: 0264-410X
DOI: 10.1016/s0264-410x(99)00407-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, Tolerability, and Lack of Antibo

Safety, Tolerability, and Lack of Antibody Responses After Administration of a Pf CSP DNA Malaria Vaccine via Needle or Needle-Free Jet Injection, and Comparison of Intramuscular and Combination Intramuscular/Intradermal Routes

✍ Epstein, Judith E.; Gorak, Edward J.; Charoenvit, Yupin; Wang, Ruobing; Freydber 📂 Article 📅 2002 🏛 Mary Ann Liebert 🌐 English ⚖ 193 KB

The safety and tolerability of an HIV-1

The safety and tolerability of an HIV-1 DNA prime–protein boost vaccine (DP6-001) in healthy adult volunteers

✍ Jeffrey S. Kennedy; Mary Co; Sharone Green; Karen Longtine; Jaclyn Longtine; Mel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 675 KB

P14-12. Safety and tolerability of VRC D

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults

✍ ME Enama, L Novik, L Holman, I Gordon, M Nason, J Ledgerwood, BS Graham 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 62 KB

Safety, Tolerability, and Pharmacokineti

Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers

✍ Hirawat, Samit; Welch, Ellen M.; Elfring, Gary L.; Northcutt, Valerie J.; Paushk 📂 Article 📅 2007 🏛 Sage Publications 🌐 English ⚖ 337 KB

Corrigendum to “Lessons from IAVI-006, a

Corrigendum to “Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers” [Vaccine 26 (2008) 6671–6677]

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Lessons from IAVI-006, a Phase I clinica

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 498 KB